English | Español

Amgen Inc.
+ Regulatory
Press release submission | Dec 20, 2021

FDA Approves Otezla® (Apremilast) for the Treatment of Adult Patients With Plaque Psoriasis, Regardless of Severity Level
+ Regulatory
Press release submission | Sep 5, 2021

New Tezepelumab Data Show 86% Reduction In Exacerbations In Patients With Severe Asthma And Comorbid Nasal Polyps
+ Technology/Innovation
Press release submission | Mar 15, 2019

AMGEN, INC.: Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke
+ Community
Carol Ostrow | Dec 15, 2017

Amgen Foundation commits $500,000 to help southern California wildfire victims
+ Regulatory
Carol Ostrow | Dec 10, 2017

Amgen's Repatha wins FDA approval
+ Community
Carol Ostrow | Dec 8, 2017

Amgen presents at Evercore conference
+ Community
Mark Iandolo | Nov 1, 2017

Cancer information awareness campaign features conversations with Joan Lunden
+ Community
Kathy Adams | Oct 22, 2017

Amgen, Boston Children's Hospital team up for study on unusual pain response

Trending
+ Pharmaceuticals
Patient Daily | Aug 4, 2026

Merck reports mixed results for tulisokibart in recent clinical trials and financial update
+ Pharmaceuticals
Patient Daily | Aug 6, 2026

FDA approves Replimune’s melanoma drug Tudriqev after advisory committee debate
+ Regulatory
M. R. Armstrong | Aug 4, 2026

Public Policy Solutions on 340B: 'The program has enriched big hospital execs'
+ Pharmaceuticals
Patient Daily | Aug 5, 2026

Bristol Myers Squibb and AstraZeneca reportedly in merger talks amid industry changes